<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600755</url>
  </required_header>
  <id_info>
    <org_study_id>09-025</org_study_id>
    <nct_id>NCT01600755</nct_id>
  </id_info>
  <brief_title>Autologous Cell Therapy for Treatment of Fecal Incontinence</brief_title>
  <official_title>A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook MyoSite</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook MyoSite</source>
  <brief_summary>
    <textblock>
      The aim of this clinical study is to investigate the safety and feasibility of Autologous
      Muscle Derived Cells (AMDC; a preparation of a patient's own cells) injection into the anal
      sphincter for treatment of patients with fecal incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to test the safety and feasibility of Autologous Muscle Derived Cells
      (AMDC) as a treatment for fecal incontinence in men and women. AMDC therapy seeks to allow
      remodeling of the external anal sphincter in patients with fecal incontinence from either
      defined structural defects to or a generalized weakening of the external anal sphincter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Incontinent Episodes</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Score</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter Pressure</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Incontinence Quality of Life Scale (FIQL)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Autologous Muscle-Derived Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cell Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Muscle-Derived Cells (AMDC)</intervention_name>
    <description>Cell Treatment</description>
    <arm_group_label>Autologous Muscle-Derived Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary symptoms of fecal incontinence, as confirmed by patient medical history and
             physical examination

          -  Wexner score â‰¥ 9

          -  Failed conservative treatment

        Exclusion Criteria:

          -  Gracilis sling repair or insertion of an artificial sphincter

          -  Inflammatory Bowel Disease

          -  Significant rectocele or rectal prolapse

          -  History of radiation treatment to the anal sphincter or adjacent structures

          -  Less than 18 years of age

          -  Pregnant, breastfeeding, or plans to become pregnant during the course of the study

          -  Neuromuscular disorder

          -  History of neoplasia within 5 years prior to enrollment, except for basal cell
             carcinoma, or is receiving or planning to receive anti-cancer medications

          -  Known bleeding diathesis or uncorrected coagulopathy

          -  Medical condition that would preclude treatment due to contraindications and/or
             warnings of concomitant medications or listed in the experimental product labeling

          -  Participating in another investigational drug or device study

          -  Unable or unwilling to provide informed consent

          -  Unable or unwilling to commit to the follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manoj J Raval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>Autologous Cell Transplantation</keyword>
  <keyword>Muscle-derived Cell</keyword>
  <keyword>Anal Incontinence</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Urinary Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

